nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.01.2008 | Original Article

The effect of ethinyl estradiol–cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome

verfasst von: Ozgur Baris Gul, Asli Somunkiran, Oguz Yucel, Fuat Demirci, Ismail Ozdemir

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

Women with polycystic ovary syndrome (PCOS) have multiple risk factors for cardiovascular disease. The cardiovascular risk marker homocysteine (Hcy) is elevated in women with PCOS. This prospective study investigated the effect of oral contraceptives containing ethinyl estradiol–cyproterone acetate (EE–CA) on serum Hcy levels in women with PCOS.

Study design

A total of 30 women with PCOS were enrolled in this prospective study. The diagnosis of PCOS was made according to the criteria of the Rotterdam PCOS consensus workshop group. All women took oral contraceptives containing EE/CA (35 μg/2 mg) for 3 months. Serum samples for Hcy, lipid profile and hormones were obtained during the early follicular phase (days 3–5) of the spontaneous or progestin-induced bleeding at baseline, and after the third treatment cycle.

Results

Three months of EE–CA therapy significantly decreased the Hcy levels from 55.97 ± 16.04 to 54.03 ± 16.15 (P = 0.01). A significant correlation was observed between the Hcy and total and free testosterone levels (r = 0.44, P = 0.015 and r = 0.46, P = 0.001 respectively).

Conclusions

Although the decrease in Hcy levels with EE–CA therapy was statistically significant, further studies are necessary to determine the clinical benefit of this treatment.

Franks S (1995) Polycystic ovary syndrome. N Eng J Med 333:853–61CrossRef

Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83:3078–3082PubMedCrossRef

Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L (2003) Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52:908–915PubMedCrossRef

ACOG practice bulletin no. 41 (2003) Polycystic ovary syndrome. Int J Gynaecol Obstet 80:335–348CrossRef

Birdsall MA, Farquhar CM, White HD (1997) Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126:32–35PubMed

Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr (1996) Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 174:1224–1229 discussion 1229–1232PubMedCrossRef

Talbott EO, Guzick DS, Sutton-Tyrrell K et al (2000) Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20:2414–2421PubMed

Talbott E, Clerici A, Berga SL et al (1998) Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 51:415–422PubMedCrossRef

Yarali H, Yildirir A, Aybar F et al (2001) Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 76:511–516PubMedCrossRef

10.

Tiras MB, Yalcin R, Noyan V et al (1999) Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod 14:1949–1952PubMedCrossRef

11.

Orio F Jr, Palomba S, Spinelli L et al. (2004) The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89:3696–3701. Erratum in: J Clin Endocrinol Metab 89:5621

12.

Auer J, Berent R, Eber B (2001) Homocysteine: a novel risk factor in vascular disease. Coron Health Care 5:89–99CrossRef

13.

Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. J Am Med Assoc 274:1049–1057CrossRef

14.

Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE (2004) Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? Clin Endocrinol (Oxf) 60:560–567CrossRef

15.

Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R (2003) Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 18:721–727PubMedCrossRef

16.

Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L (2002) The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 53:157–162PubMedCrossRef

17.

Godsland IF, Crook D, Simpson R, et al (1990) The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323:1375–1381PubMedCrossRef

18.

Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V (1992) Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 74:64–70PubMedCrossRef

19.

Gossain VV, Sherma NK, Michelakis AM, Rovner DR (1983) Effect of oral contraceptives on plasma glucose, insulin, and glucagon levels. Am J Obstet Gynecol 147:618–623PubMed

20.

Obwegeser R, Hohlagschwandtner M, Sinzinger H (1999) Homocysteine-a pathophysiological cornerstone in obstetrical and gynaecological disorders? Hum Reprod Update 5:64–72 ReviewPubMedCrossRef

21.

Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19–25CrossRef

22.

Ashwell M, Chinn S, Stalley S, Garrow JS (1982) Female fat distribution-a simple classification based on two circumference measurements. Int J Obes 6:143–152PubMed

23.

Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440–1447PubMed

24.

American Diabetes Association (1997) Report of the expert committee on the diagnosis and classification of Diabetes Mellitus. Diabetes Care 20:1183–1197

25.

Legro RS, Urbanek M, Kunselman AR, Leiby BE, Dunaif A (2002) Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. Fertil Steril 78:51–57PubMedCrossRef

26.

Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929–1935PubMedCrossRef

27.

Pasquali R, Patton L, Pagotto U, Gambineri A (2005) Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome. Minerva Ginecol 57:79–85 ReviewPubMed

28.

Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165–1174PubMedCrossRef

29.

Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L (1995) Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15:821–826PubMed

30.

Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N (2001) Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453–2455PubMedCrossRef

31.

Randeva HS, Lewandowski KC, Drzewoski J, et al (2002) Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87:4496–4501PubMedCrossRef

32.

Orio F Jr, Palomba S, Di Biase S, et al (2003) Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:673–679PubMedCrossRef

33.

Yilmaz M, Biri A, Bukan N, et al (2005) Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 20:258–263PubMedCrossRef

34.

Vryonidou A, Papatheodorou A, Tavridou A, et al (2005) Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:2740–2746PubMedCrossRef

35.

Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB (1985) Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61:946–951PubMedCrossRef

36.

Korytkowski MT, Mokan M, Horwitz MJ, Berga SL (1995) Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 80:3327–3334PubMedCrossRef

37.

Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC (2005) Effects of metformin and ethinyl estradiol–cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 152:269–275PubMedCrossRef

38.

Cibula D, Fanta M, Vrbikova J, et al (2005) The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod 20:180–184PubMedCrossRef

39.

Elter K, Imir G, Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol–cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 17:1729–1737PubMedCrossRef

40.

Graham IM, Daly LE, Refsum HM, et al (1997) Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA 277:1775–1781PubMedCrossRef

41.

Vrbikova J, Cibula D (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11:277–291PubMedCrossRef

42.

ESHRE Capri Workshop Group (2001) Ovarian and endometrial function during hormonal contraception. Hum Reprod 16:1527–1535 (review)CrossRef

43.

Merki-Feld GS, Imthurn B, Keller PJ (2002) Effects of two oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism. Metabolism 51:1216–1221PubMedCrossRef

44.

Seeger H, Petersen G, Schulte-Wintrop E, Teichmann AT, Mueck AO (2002) Effect of two oral contraceptives containing ethinylestradiol and levonorgestrel on serum and urinary surrogate markers of endothelial function. Int J Clin Pharmacol Ther 40(4):150–157PubMed

45.

Ehrmann AD (2005) Polycystic ovary syndrome. N Eng J Med 352:1223–1236CrossRef

Titel: The effect of ethinyl estradiol–cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome
verfasst von: Ozgur Baris Gul
Asli Somunkiran
Oguz Yucel
Fuat Demirci
Ismail Ozdemir
Publikationsdatum: 01.01.2008
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 1/2008
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-007-0401-x

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

The effect of ethinyl estradiol–cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome

Abstract

Objective

Study design

Results

Conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Rezidivierender Peritonsillarabszess nach Oralsex

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

Update Gynäkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Objective

Study design

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine

The “catheter bag” sign revisited: a simple way detecting bladder trauma during operative laparoscopic procedures

Sudden cardiac arrest during cesarean section due to epidural anaesthesia using ropivacaine: a case report

Relation between vaginal and endocervical pH in patients undergoing cold-knife conization and hysterectomy

Sexual function after surgery for stress urinary incontinence: vaginal sling versus Burch colposuspension

Congenital diaphragmatic hernia, etiology and management, a 10-year analysis of a single center

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Rezidivierender Peritonsillarabszess nach Oralsex

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

Update Gynäkologie